Epidemiology of Cardiotoxicity in Children With Cancer
NCT00005418 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2016-03-16
Summary
To provide a comprehensive analysis of risk factors for the development of clinical cardiotoxicities in over 6,000 children with cancer who had been treated on standardized protocols involving the use of anthracyclines alone or in combination with other potentially cardiotoxic therapies or with no use of anthracycline therapy.
Conditions
- Cardiovascular Diseases
- Heart Diseases
- Heart Failure, Congestive
- Death, Sudden, Cardiac
- Heart Failure
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Eligibility
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1992-04-30
- Completion
- 1994-03-31
More Related Trials
-
Pharmacokinetics of Drugs Administered to Children
NCT03481881 ·Status: RECRUITING
-
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
NCT02717507 ·Status: COMPLETED ·Phase: PHASE2
-
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
NCT00053963 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer
NCT00897871 ·Status: UNKNOWN
-
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916 ·Status: RECRUITING ·Phase: PHASE3
-
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
NCT00003070 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
NCT00003423 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
NCT02354547 ·Status: SUSPENDED ·Phase: PHASE1
-
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia
NCT00001689 ·Status: COMPLETED ·Phase: PHASE1
-
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
NCT00101270 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
NCT00003735 ·Status: COMPLETED ·Phase: PHASE2
-
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
NCT03107988 ·Status: COMPLETED ·Phase: PHASE1
-
Cardiac Tumors in Children
NCT00215085 ·Status: TERMINATED
-
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
NCT00742495 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
NCT00057811 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
NCT00004919 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
NCT00491946 ·Status: UNKNOWN ·Phase: PHASE4
-
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
NCT01418495 ·Status: COMPLETED
-
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
NCT00016861 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338 ·Status: RECRUITING ·Phase: PHASE3
-
Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy
NCT00001387 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
NCT00003650 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
NCT00003178 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
NCT00005578 ·Status: COMPLETED ·Phase: PHASE3
-
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
NCT00458744 ·Status: WITHDRAWN ·Phase: PHASE1